China ; Humans ; Liver Neoplasms ; prevention & control ; therapy

In Vietnam, the rate of chronic hepatitis B was very high (15-20%). The rate of chronic hepatitis C (was 2-3%) but increasingly. Especially, these rates among addicts were very high. They were two major causes of the primary liver cancer, followed by alcoholism and use of aflatoxin. Therefore, the program of primary liver cancer prevention should concentrate the hepatitis B and hepatitis C prevention and control a well as risk of alcoholism and use of aflatoxin
Liver Neoplasms ; Hepatitis B ; prevention & control

In order to standardize the effective prevention, early screening and diagnosis of the population at risk of primary liver cancer, the Chinese Society of Hepatology and Chinese Medical Association organized the relevant domestic experts to formulate the "Consensus on Secondary Prevention of Primary Liver Cancer (2021 version)," based on the basic, clinical and preventive research progress, combined with the actual situation at home and abroad, so as to provide an important basis for the prevention, screening and early diagnosis of primary liver cancer in the population of chronic liver disease.
Carcinoma, Hepatocellular/prevention & control* ; Consensus ; Gastroenterology ; Humans ; Liver Cirrhosis ; Liver Neoplasms/prevention & control* ; Mass Screening ; Secondary Prevention

In order to effectively prevent recurrence, improve the prognosis and increase the survival rate of primary liver cancer (PLC) patients with radical cure, the Chinese Society of Hepatology, Chinese Medical Association organized the relevant experts to develop the consensus on tertiary prevention of PLC (2022 version), which based on domestic and international research progress on the risk factors, pathological and clinical features, prevention of recurrence of PLC, combined with the present actual situation in China. The purpose is to provide a current basis for the prevention, surveillance, early detection and diagnosis, the effective measures of PLC recurrence.
China/epidemiology* ; Consensus ; Humans ; Liver Neoplasms/prevention & control* ; Survival Rate ; Tertiary Prevention

Carcinoma, Hepatocellular ; pathology ; prevention & control ; Hepatectomy ; Humans ; Liver Neoplasms ; pathology ; prevention & control ; Neoplasm Recurrence, Local ; prevention & control ; therapy ; Postoperative Period

OBJECTIVETo assess the protective effect of drinking green tea on the development of gastric, liver and esophageal cancers.

METHODSA population based study was conducted in Taixing, Jiangsu province, including 206, 204, 218 cases, respectively, and 415 population controls.

RESULTSGreen tea decreased the development of gastric cancer risk by 40%. Dose-response relationships were observed between the length of time, concentration and quantity of green tea drinking and its protective effects on gastric cancer. For individuals who drink green tea for more than 250 g per month, the risk of gastric cancer reduced about 60%. Green tea might have protective effect on liver cancer. However, no protective effect of green tea was observed on esophageal cancer.

CONCLUSIONGreen tea drinking might be a protective factor for gastric cancer. However, the protective effects of green tea on liver and esophageal cancer were not obvious.

Dose-Response Relationship, Drug ; Esophageal Neoplasms ; prevention & control ; Humans ; Liver Neoplasms ; prevention & control ; Plant Extracts ; therapeutic use ; Stomach Neoplasms ; prevention & control ; Tea ; chemistry

China ; Hepatitis B, Chronic ; complications ; Humans ; Liver Cirrhosis ; surgery ; virology ; Liver Neoplasms ; surgery ; Liver Transplantation ; trends ; Secondary Prevention ; Tissue Donors

Objective: To analyze the data of malignant tumor mortality and change in disease burden in Hebei province from 1973 to 2013. Methods: Cancer mortality rate, age-standardized mortality rate and the years of life lost due to premature mortality (YLLs) were calculated by using the data from three rounds of all death causes survey and database of cancer registry in Hebei during 1973-2013. Results: From 1973 to 2013, a linear upward of malignant tumor mortality was observed, with a 51.57% increase. The mortality rate during 1973-1975 was 98.52/100 000 and it was 149.33/100 000 during 2011-2013. During 1973-1975, the YLLs was 17.0/1 000 in males and 12.8/1 000 in females. While during 2011-2013, the YLLs was 23.2/1 000 in males and 15.9/1 000 in females. During 1973-1975, esophagus cancer, stomach cancer and liver cancer were top three leading causes of deaths. During 2011-2013, lung cancer, stomach cancer and liver cancer were main leading causes of deaths. During the past 40 years, the deaths of esophagus cancer and cervix cancer decreased dramatically, but the deaths of lung cancer and breast cancer increased sharply. Conclusions: The disease burden caused by malignant tumor is becoming more serious in Hebei. It is necessary to strengthen the primary prevention and screening of malignant tumor.
Breast Neoplasms ; Esophageal Neoplasms ; Female ; Humans ; Liver Neoplasms ; Lung Neoplasms ; Male ; Mortality/trends* ; Mortality, Premature ; Neoplasms/mortality* ; Primary Prevention ; Reference Standards ; Registries ; Stomach Neoplasms ; Uterine Cervical Neoplasms

Carcinoma, Hepatocellular ; surgery ; Catheter Ablation ; adverse effects ; Humans ; Liver Neoplasms ; surgery ; Postoperative Complications ; etiology ; prevention & control

Cancer prevention is a challenging project both in the basic and clinical medicine. In particular, prevention of liver cancer is the most urgent task in countries where the incidence of hepatitis virus-related liver cancer is rising. As reviewed in this article, liver cancer is going to be the first cancer that will be actually prevented by primary and secondary interventions. Even the improvement of absolute survival of the patients can be expected by successful prevention, as already demonstrated in a few clinical trials. Thus, prevention of liver cancer is promising to provide not only cost-effectiveness by morbidity reduction but also cost-benefit by mortality improvement.
Animals ; Chemoprevention ; Hepatitis B/complications/drug therapy ; Human ; Liver Neoplasms/etiology/*prevention & control ; Retinoids/*therapeutic use